Liver artery chemotherapy for non-surgical bile duct cancer
Part of Cancer clinical trials.
This trial tests delivering two chemotherapy medicines directly into the liver’s artery in people with bile duct cancer inside the liver that cannot be removed with curative surgery. It aims to control the cancer after first-line treatment and see how well this targeted approach works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have intrahepatic (inside the liver) cholangiocarcinoma confirmed by biopsy after first-line treatment
- Your scans show no spread outside the liver and no fluid buildup in the abdomen (ascites)
- Your general health is good enough for treatment (performance status 0–1) and you are expected to live more than 3 months
- The tumor cannot be safely removed with curative-intent surgery (checked by a specialist team)
- Blood counts and kidney/liver tests meet safety limits (including enough platelets, blood cells, and kidney function)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a three-drug combination (TACE plus two immune-related drugs) against a standard chemo-immunotherapy regimen for people with a liver cancer that can't be surgically removed. It aims to see if the new approach can shrink tumors and improve outcomes.
This trial is testing a treatment plan that first delivers chemotherapy directly into the liver (through a thin tube) along with standard IV chemotherapy. The goal is to shrink the tumor enough to allow for surgery or less aggressive treatment later. It is for people with bile duct or gallbladder cancer that has not spread far.
This trial tests giving chemotherapy directly into the liver artery after surgery to remove liver tumors. It's for people with colorectal cancer that spread to the liver, who have a high chance of the cancer coming back.
This trial tests a combination of chemotherapy drugs (gemcitabine, cisplatin, nab-paclitaxel) with an immunotherapy (rilvegostomig) before and after surgery for intrahepatic cholangiocarcinoma that can be completely removed. It aims to see if this approach improves outcomes.
This trial tests a combination of a targeted drug (lenvatinib), an immunotherapy (PD-1 inhibitor), and chemotherapy given directly into the liver's blood supply for people with advanced intrahepatic cholangiocarcinoma (a type of bile duct cancer that starts in the liver). The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a special type of chemotherapy (hepatic artery infusion) for people with cancers that have spread to the liver, such as colorectal cancer or bile duct cancer (intrahepatic cholangiocarcinoma). It studies whether delivering this treatment partly at a community center and partly at a university hospital is safe and feasible.
Hear when a new Cholangiocarcinoma Non-resectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.